ADCTADC Therapeutics SA

NYSE · US · Healthcare · Drug Manufacturers - Specialty & Generic · adctherapeutics.com

0.9966USDMkt Cap: 127.23M $P/E: —3d ago

ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S…

Industry Peers

Drug Manufacturers - Specialty & Generic

Screen all

MRK

MERCK Kommanditgesellschaft auf Aktien

$65.19BUSDP/E 23.7

TAK

Takeda Pharmaceutical Co. Ltd.

$58.06BUSD

HLN

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

$43.98BUSDP/E 20.4

TEVA

Teva Pharmaceutical Industries Limited

United Therapeutics Corporation

Swedish Orphan Biovitrum AB

Neurocrine Biosciences, Inc.

$15.51BUSDP/E 22.3

ELAN

Elanco Animal Health Incorporat

$11.98BUSD

RDY

Dr. Reddy's Laboratories Ltd

Hims & Hers Health, Inc.

$7.88BUSD

LNTH

Lantheus Holdings Inc

$6.53BUSDP/E 23.9

AMRX

Amneal Pharmaceuticals, Inc. Class A

Kiniksa Pharmaceuticals, Ltd.

$6.08BUSDP/E 79.8

Key Statistics

Company

Market Cap127.23M $

Enterprise Value346.32M $

Revenue (TTM)79.58M $

Gross Profit75.56M $

Net Income (TTM)-142.62M $

Revenue/Share0.5340 USD

Last Price0.9966 USD

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees188

CountryUS

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)-0.67

PEG—

EV/EBITDA-3.70

EV/Revenue4.35

P/S1.60

P/B-0.56

EPS (TTM)-0.58

EPS (Forward)-1.49

52W Range

0.970089% of range1.000

52W High1.000 USD

52W Low0.9700 USD

Profitability

Gross Margin92.87%

Oper. Margin-118.14%

EBITDA Margin-117.75%

Profit Margin-175.31%

ROE76.75%

ROA-44.14%

Growth

Revenue Growth2.20%

Earnings Growth—

Cash Flow & Leverage

Operating CF-141.17M $

CapEx (TTM)264.00K $

FCF Margin-85.59%

FCF Yield-53.54%

Net Debt219.08M $

Net Debt/EBITDA-2.34

Balance Sheet

Debt/Equity-0.63

Current Ratio3.03

Quick Ratio2.86

Book Value/Sh-1.7910 USD

Cash/Share1.716 USD

Dividends

Fwd Div Rate—

Trail. Div Rate0.0000 USD

Div. Yield—

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating1.8 (Buy)

Strong BuyBuyHoldSellStr. Sell

Target (Mean)3.333 USD

Upside (mean)+234.5%

Target Range2.000 USD – 5.000 USD

$2.000+234.5% to mean$5.000

# Analysts3

Ownership

Shares Out.127.67M

Float88.56M

Insiders14.42%

Institutions67.54%

Short Interest

Short Ratio4.7d

Short % Float4.72%

Short % Out.4.00%

Shares Short5.09M

Short (prev mo.)5.99M

Technical

SMA 501.139 (-12.5%)

SMA 2003.107 (-67.9%)

Beta1.83

S&P 52W Chg19.18%

Avg Vol (30d)938.29K

Avg Vol (10d)1.79M

Technical Indicators

RSI (14)—

MACD—

MACD Signal—

MACD Hist.—

BB Upper—

BB Middle—

BB Lower—

BB Width—

ATR (14)—

Vol Ratio (20d)—